TrivarX Builds the Runway for Stabl-Im Human Testing

Stabl-Im Moves Toward Human Testing

TrivarX Limited (ASX:TRI) has set an indicative path toward its first human study of Stabl-Im, targeting ethics submission in the fourth quarter of calendar 2026 and first participant enrolment in the first quarter of 2027. Initial clinical study results are pencilled in for Q2 CY27, although the company cautions that the timeline remains subject to normal clinical development considerations.

The stable isotope-enhanced MRI platform is not yet producing clinical data. Instead, TrivarX is building the infrastructure needed to generate it: pre-clinical studies have commenced, investigational product has been received and is being prepared for individual participants under applicable Therapeutic Goods Administration requirements.

Specialist Analysis Adds a Technical Dependency

A notable part of the preparation is the measurement of deuterium in plasma, which TrivarX says is not routinely available through conventional clinical trial laboratories. The company is advancing discussions with a preferred specialist vendor to establish and optimise the analytical method for samples generated during the study.

That work will need to sit alongside MRI procedures, investigational product preparation and the clinical protocol. TrivarX says it is seeking a clinical site and Principal Investigator with experience in healthy-volunteer studies, with the formal selection process now underway. A clinical trial manager has also joined the team to support study start-up and execution.

Indicative Milestones Extend Into 2027

The company says pre-clinical study design and testing requirements were finalised in Q2 CY26, with the studies beginning in Q3 and expected to conclude in November. Its announcement describes the clinical feasibility and plasma enrichment study design requirements as completed, while the accompanying milestone table lists that work as underway, suggesting some finalisation activity remains.

Ethics preparation is scheduled for Q4 CY26, followed by an anticipated committee determination in January 2027. Recruitment is expected to finish in Q2 CY27, when TrivarX also expects to have initial data available. Separate non-clinical studies are examining additional potential applications for Stabl-Im, with results expected in the final quarter of 2026.

The next meaningful tests are therefore operational rather than clinical: completion of the pre-clinical work, selection of the site and investigator, validation of the deuterium assay and a successful ethics process. Until those steps are cleared, the Q1 enrolment target remains a plan rather than a clinical milestone delivered.